Skip to content
Open access

Pathological Complete Response and Safety of Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy in Triple-Negative and Hormone Receptor-Low Breast Cancer: A Real-World Cohort Study

Sep 2026 · Breast Cancer · Vol 18 · 0 citations · 41 references
Medicine

TL;DR

In this real-world Middle Eastern cohort, pembrolizumab-based chemoimmunotherapy achieved pCR rates consistent with pivotal trial data, and Grade 3 histology, pathogenic germline mutation, and age younger than 40 years were independently associated with pCR.

Abstract

Background Neoadjuvant pembrolizumab-based chemoimmunotherapy is standard of care for early-stage triple-negative breast cancer (TNBC). Real-world data remain limited outside trial populations, particularly in the Middle East, and hormone receptor (HR)-low tumors (ER/PR 1–10%) are undercharacterised in this setting. Methods We conducted a retrospective cohort study of 149 patients with non-metastatic TNBC or HR-low breast cancer at King Hussein Cancer Center, Jordan (April 2021–September 2024). Primary endpoint was pCR (ypT0/Tis ypN0), analysed across all 149 treatment-initiated patients with the 7 who did not undergo surgery classified as non-pCR; Firth penalised logistic regression identified factors independently associated with pCR. Safety was assessed in all 149. Results The overall pCR rate was 59.1% (88/149). On Firth penalised multivariable logistic regression, three variables were independently associated with pCR: grade 3 histology (aOR 4.44, 95% CI 1.61–13.66, p = 0.004), pathogenic germline mutation (aOR 3.19, 95% CI 1.26–9.11, p = 0.014), and age younger than 40 years (aOR 2.82, 95% CI 1.20–7.10, p = 0.017). HR-low tumors (n = 15) achieved 66.7% pCR, comparable to HR-negative disease (58.2%). Immune-related adverse events occurred in 44 patients (29.5% of 149); grade ≥3 events in 9 (20.5% of irAE patients; 6.0% of the cohort); permanent immunotherapy discontinuation for treatment-limiting toxicity in 6 (13.6% of irAE patients; 4.0% of the cohort). Hospitalization occurred in 33.6%, predominantly due to febrile neutropenia. At a median follow-up of 27.3 months, 137 of 149 patients (91.9%) were alive and 136 (91.3%) were recurrence-free; all 13 recurrences were distant. Among surgical patients, disease-free survival was 96.6% in the pCR group versus 85.2% with residual disease (log-rank p = 0.011). Conclusion In this real-world Middle Eastern cohort, pembrolizumab-based chemoimmunotherapy achieved pCR rates consistent with pivotal trial data. Grade 3 histology, pathogenic germline mutation, and age younger than 40 years were independently associated with pCR; the HR-low findings are exploratory. These results support prospective biomarker-driven trials in early TNBC across underrepresented populations.

Read PDF

Similar papers

Review Sep 2026

Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab-based chemoimmunotherapy in early triple-negative breast cancer and its clinical significance.

AIMS To characterize the heterogeneity of pathological responses in the breast and regional lymph nodes after neoadjuvant pembrolizumab-based chemoimmunotherapy in early-stage triple-negative breast cancer (TNBC) and to explore their clinical implications. METHODS AND RESULTS A total of 203 patients with TNBC treated...

Jiwon Koh, K. J. Suh, H. Park et al. · 0 citations
Open access Aug 2026

Pathologic complete response (pCR) rate and factors associated with pCR after taxane, trastuzumab, and pertuzumab in HER2-positive breast cancer: secondary analyses of EA1181

Neoadjuvant THP achieved pCR in nearly two-thirds of patients with HER2+/ER− and one-third with HER2+/ER+ breast cancer, and these findings should help optimize risk stratification and treatment personalization for patients with HER2-positive breast cancer.

N. Tung, Feng-Min Zhao, A. DeMichele et al. · 2 citations
Open access Sep 2026

Pathologic complete response and survival according to germline BRCA1/2 status in triple-negative breast cancer

Germline BRCA1/2 pathogenic variants (gBRCA-PV) are associated with chemosensitivity in triple-negative breast cancer (TNBC), but whether higher pathologic complete response (pCR) rates translate into improved long-term outcomes remains uncertain. We assessed associations of gBRCA-PV status with pCR, recurrence-free su...

Paulina Gebhart, F. Heinzl, C. Kahl et al. · 0 citations
Open access Sep 2026

Safety, treatment delivery, and pathological response before and after pembrolizumab implementation for early ER-negative, HER2-normal breast cancer

Background Pembrolizumab has become standard neoadjuvant systemic therapy (NST) for early estrogen receptor (ER)-negative, human epidermal growth factor receptor 2 (HER2)-normal early breast cancer (eBC). Electronic health record (EHR) data may support real-world assessment of its implementation in routine care. Patien...

A. Henriksen, A. Lundgren, M. Andersen et al. · 0 citations
Open access Sep 2026

Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes

Triple‑negative breast cancer (TNBC) is an aggressive disease with poor survival outcomes. With the integration of immunotherapy, the optimal neoadjuvant chemotherapy backbone remains poorly defined. We examined real-world treatment patterns and response rates among patients receiving a carboplatin-based regimen, with...

Matthew R. Kroll, Mary C. Schroeder, J. M. Neuner et al. · 0 citations
Open access Sep 2026

Neoadjuvant pembrolizumab-based therapy versus dual HER2 blockade in early breast cancer: comparable surgical complication rates in a real-world cohort

The findings support the feasibility of integrating both neoadjuvant treatment strategies into routine surgical practice; however, confirmation in larger prospective studies is warranted.

K. Wimmer, Katharina Kantner, R. Exner et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.